

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 55011

Title: Predictive indicators of successful TKI discontinuation in patients with chronic myeloid leukemia

Reviewer's code: 01166697

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Spain

Manuscript submission date: 2020-03-21

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2020-09-04 08:33

Reviewer performed review: 2020-09-14 10:53

Review time: 10 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

In this review the authors summarized the factors that predict whether a patient with chronic myeloid leukemia (CML) treated for several years with tyrosine kinase inhibitors (TKIs) will successfully achieve treatment free remission (TFR), that is, if they can successfully discontinue treatment without relapsing. The topic is interesting, however the review lacks of figures and/or tables that could help the readers to follow the text. Sometimes the paragraphs are not well distinguished among them and seem a repetition of each other. In the introduction few information should be added regarding CML before introducing the FDA treatment. Few information should be also given about tyrosine kinases and their inhibitors (TKI). Predictive indicators of successful TKI discontinuation in patients with chronic myeloid leukemia, as stated in the title, should be clearly underlined in the conclusion part of the review.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 55011

Title: Predictive indicators of successful TKI discontinuation in patients with chronic myeloid leukemia

Reviewer's code: 01166697

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Spain

Manuscript submission date: 2020-03-21

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2020-09-29 09:20

Reviewer performed review: 2020-09-29 09:37

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

The authors have addressed the reviewer's comments and improved the quality of the manuscript. Still some points need to be amended: In the introduction please add abbreviation "CML": "Chronic myeloid leukemia (CML) is a neoplasia of the pluripotent hematopoietic progenitor cells characterized by the clonal expansion..." In general check if all the abbreviations have been extensively explained at first appearance. Please define MPNs : ..."molecular basis of the MPNs". Please add references: "CML is defined by the presence of a reciprocal translocation between chromosomes 9 and 22 t(9;22)(q34;q11), resulting in a shortened chromosome 22 known as the Philadelphia chromosome, which leads to the expression of the fusion oncogene BCR-ABL1 encoding a constitutively active tyrosine kinase". "Imatinib mesylate (Gleevec®) was the first tyrosine kinase inhibitor (TKI) developed to specifically target the BCR-ABL1 oncoprotein. Physicians now have five approved TKIs available for the treatment of patients with CML: dasatinib (Sprycel), nilotinib (Tasigna), and bosutinib (Bosulif) for first- or second-line therapy and ponatinib (Iclusig) for patients with resistance or intolerance to prior therapy".